BOSTON SCIENTIFIC CORP — Director's Dealing 2020

Jan 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BOSTON SCIENTIFIC CORP (BSX)
CIK: 0000885725
Period of Report: 2020-01-01

Reporting Person: Nanavaty Maulik (SVP & Pres, Neuromodulation)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-01	Common Stock	M	7950.0000	$0.0000	Acquired	263144.0000	Direct
2020-01-01	Common Stock	F	2925.0000	$45.2200	Disposed	260219.0000	Direct
2020-01-02	Common Stock	M	6616.0000	$16.3100	Acquired	266835.0000	Direct
2020-01-02	Common Stock	M	3007.0000	$13.0800	Acquired	269842.0000	Direct
2020-01-02	Common Stock	S	9623.0000	$45.3304	Disposed	260219.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-01-01	Performance Share Units	$	M	7950.0000	Disposed	2019-12-31	Common Stock (7950.0000)	Direct
2020-01-02	Stock Option (Right to Buy)	$16.3100	M	6616.0000	Disposed	2025-02-23	Common Stock (6616.0000)	Direct
2020-01-02	Stock Option (Right to Buy)	$13.0800	M	3007.0000	Disposed	2024-02-24	Common Stock (3007.0000)	Direct

Footnotes

F1: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019.

F2: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

F3: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $45.21 to $45.55, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F6: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

F7: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.